% | $
Quotes you view appear here for quick access.

CSX Corp. Message Board

nobleonetoo 1 post  |  Last Activity: Sep 16, 2015 7:58 PM Member since: Dec 23, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • by nobleonetoo Sep 16, 2015 7:58 PM Flag

    Investors have been bidding up shares of Acadia for years now, as Nuplazid looks like it could be the real deal. It has been granted the much coveted "breakthrough therapy" designation by the FDA, and it offers hope to patients who suffer from Parkinson's Disease Psychosis, which is a disease that currently has no real treatment options.

    Analysts expect big things from Nuplazid, with peak sales currently expected to eclipse more than $2 billion. However, the company is also currently in phase 2 testing for the compound used in Nuplazid, called pimavanzserin, as a treatment for Alzheimer's Disease Psychosis and Schizophrenia, which could certainly push that estimate higher.

28.60+0.17(+0.60%)Dec 1 4:01 PMEST